Patents Assigned to DiaTex, Inc.
  • CB-0406 tromethamine salt
    Publication number: 20210355065
    Abstract: CB-0406 tromethamine salt, especially in crystalline form and as an ansolvate, methods of preparing it, compositions containing it, and its pharmaceutical uses.
    Type: Application
    Filed: May 12, 2021
    Publication date: November 18, 2021
    Applicants: CymaBay Therapeutics, Inc., DiaTex, Inc.
    Inventors: Stephan X.M. Boerrigter, Charles A. McWherter, Robert L. Martin, Jennifer L. Nelson, Jiangao Song
  • CB-0406 choline salt
    Publication number: 20210355066
    Abstract: CB-0406 choline salt, especially in crystalline form and as an ansolvate, methods of preparing it, compositions containing it, and its pharmaceutical uses.
    Type: Application
    Filed: May 12, 2021
    Publication date: November 18, 2021
    Applicants: CymaBay Therapeutics, Inc., DiaTex, Inc.
    Inventors: Stephan X.M. Boerrigter, Charles A. McWherter, Robert L. Martin, Jennifer L. Nelson, Jiangao Song
  • Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent
    Patent number: 10137112
    Abstract: Disclosed herein are pharmaceutical compositions, methods and kits for lowering the serum uric acid level of a subject and for the treatment of a condition associated with elevated serum uric acid levels comprising administering a composition comprising a first urate-lowering agent and a second urate-lowering agent. In some aspects the first urate-lowering agent is (?)-halofenate, (?)-halofenic acid, or a pharmaceutically acceptable salts thereof. In some aspects the second urate-lowering agent is an inhibitor of uric acid production, a uricosuric agent, a uricase, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: October 2, 2017
    Date of Patent: November 27, 2018
    Assignees: CymaBay Therapeutics, Inc., DiaTex, Inc.
    Inventors: Brian K. Roberts, Gopal Chandra Saha, Brian Edward Lavan, Charles A. McWherter
  • Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent
    Publication number: 20180214420
    Abstract: Disclosed herein are pharmaceutical compositions, methods and kits for lowering the serum uric acid level of a subject and for the treatment of a condition associated with elevated serum uric acid levels comprising administering a composition comprising a first urate-lowering agent and a second urate-lowering agent. In some aspects the first urate-lowering agent is (?)-halofenate, (?)-halofenic acid, or a pharmaceutically acceptable salts thereof. In some aspects the second urate-lowering agent is an inhibitor of uric acid production, a uricosuric agent, a uricase, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: October 2, 2017
    Publication date: August 2, 2018
    Applicants: CymaBay Therapeutics, Inc., DiaTex, Inc.
    Inventors: Brian K. Roberts, Gopal Chandra Saha, Brian Edward Lavan, Charles A. McWherter
  • Crystalline solid and amorphous forms of (?)-halofenate and methods related thereto
    Patent number: 9845285
    Abstract: The present invention provides crystalline solid and amorphous forms of (?)-halofenate. The crystalline solid forms may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of conditions associated with blood lipid deposition in a mammal, particularly those diseases related to Type 2 diabetes and hyperlipidemia. The invention also relates to a method for preventing or treating Type 2 diabetes and hyperlipidemia in a mammal comprising the step of administering a therapeutically effective amount of crystalline solid and amorphous forms of (?)-halofenate.
    Type: Grant
    Filed: December 3, 2015
    Date of Patent: December 19, 2017
    Assignees: CymaBay Therapeutics, Inc., DiaTex, Inc.
    Inventors: Edward D. Daugs, Eric J. Hagen, Jason A. Hanko, David H. Louks
  • Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent
    Patent number: 9801860
    Abstract: Disclosed herein are pharmaceutical compositions, methods and kits for lowering the serum uric acid level of a subject and for the treatment of a condition associated with elevated serum uric acid levels comprising administering a composition comprising a first urate-lowering agent and a second urate-lowering agent. In some aspects the first urate-lowering agent is (?)-halofenate, (?)-halofenic acid, or a pharmaceutically acceptable salts thereof. In some aspects the second urate-lowering agent is an inhibitor of uric acid production, a uricosuric agent, a uricase, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: November 18, 2015
    Date of Patent: October 31, 2017
    Assignees: CymaBay Therapeutics, Inc., DiaTex, Inc.
    Inventors: Brian K. Roberts, Gopal Chandra Saha, Brian Edward Lavan, Charles A. McWherter
  • Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent
    Patent number: 9439891
    Abstract: Disclosed herein are pharmaceutical compositions, methods and kits for lowering the serum uric acid level of a subject and for the treatment of a condition associated with elevated serum uric acid levels comprising administering a composition comprising a first urate-lowering agent and a second urate-lowering agent. In some aspects the first urate-lowering agent is (?)-halofenate, (?)-halofenic acid, or a pharmaceutically acceptable salts thereof. In some aspects the second urate-lowering agent is an inhibitor of uric acid production, a uricosuric agent, a uricase, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 24, 2015
    Date of Patent: September 13, 2016
    Assignees: CymaBay Therapeutics, Inc., DiaTex, Inc.
    Inventors: Brian K. Roberts, Gopal Chandra Saha, Brian Edward Lavan, Charles A. McWherter
  • Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent
    Patent number: 9433612
    Abstract: Disclosed herein are pharmaceutical compositions, methods and kits for lowering the serum uric acid level of a subject and for the treatment of a condition associated with elevated serum uric acid levels comprising administering a composition comprising a first urate-lowering agent and a second urate-lowering agent. In some aspects the first urate-lowering agent is (?)-halofenate, (?)-halofenic acid, or a pharmaceutically acceptable salts thereof. In some aspects the second urate-lowering agent is an inhibitor of uric acid production, a uricosuric agent, a uricase, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: May 4, 2015
    Date of Patent: September 6, 2016
    Assignees: CymaBay Therapeutics, Inc., DiaTex, Inc.
    Inventors: Brian K. Roberts, Gopal Chandra Saha, Brian Edward Lavan, Charles A. McWherter
  • Crystalline solid and amorphous forms of (?)-halofenate and methods related thereto
    Patent number: 9233914
    Abstract: The present invention provides crystalline solid and amorphous forms of (?)-halofenate. The crystalline solid forms may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of conditions associated with blood lipid deposition in a mammal, particularly those diseases related to Type 2 diabetes and hyperlipidemia. The invention also relates to a method for preventing or treating Type 2 diabetes and hyperlipidemia in a mammal comprising the step of administering a therapeutically effective amount of crystalline solid and amorphous forms of (?)-halofenate.
    Type: Grant
    Filed: February 25, 2015
    Date of Patent: January 12, 2016
    Assignees: CYMABAY THERAPEUTICS, INC., DIATEX, INC.
    Inventors: Edward D. Daugs, Eric J. Hagen, Jason A. Hanko, David H. Louks
  • Crystalline Solid and Amorphous Forms of (-)-Halofenate and Methods Related Thereto
    Publication number: 20140024852
    Abstract: The present invention provides crystalline solid and amorphous forms of (?)-halofenate. The crystalline solid forms may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of conditions associated with blood lipid deposition in a mammal, particularly those diseases related to Type 2 diabetes and hyperlipidemia. The invention also relates to a method for preventing or treating Type 2 diabetes and hyperlipidemia in a mammal comprising the step of administering a therapeutically effective amount of crystalline solid and amorphous forms of (?)-halofenate.
    Type: Application
    Filed: July 10, 2013
    Publication date: January 23, 2014
    Applicants: Diatex, Inc., Metabolex, Inc.
    Inventors: Edward D. Daugs, Eric J. Hagen, Jason A. Hanko, David H. Louks
  • Crystalline Solid and Amorphous Forms of (-)-Halofenate and Methods Related Thereto
    Publication number: 20120232303
    Abstract: The present invention provides crystalline solid and amorphous forms of (?)-halofenate. The crystalline solid forms may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of conditions associated with blood lipid deposition in a mammal, particularly those diseases related to Type 2 diabetes and hyperlipidemia. The invention also relates to a method for preventing or treating Type 2 diabetes and hyperlipidemia in a mammal comprising the step of administering a therapeutically effective amount of crystalline solid and amorphous forms of (?)-halofenate.
    Type: Application
    Filed: May 11, 2012
    Publication date: September 13, 2012
    Applicants: Diatex, Inc., Metabolex, Inc.
    Inventors: Edward D. Daugs, Eric J. Hagen, Jason A. Hanko, David H. Louks
  • Crystalline solid and amorphous forms of (?)- halofenate and methods related thereto
    Patent number: 8203019
    Abstract: The present invention provides crystalline solid and amorphous forms of (?)-halofenate. The crystalline solid forms may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of conditions associated with blood lipid deposition in a mammal, particularly those diseases related to Type 2 diabetes and hyperlipidemia. The invention also relates to a method for preventing or treating Type 2 diabetes and hyperlipidemia in a mammal comprising the step of administering a therapeutically effective amount of crystalline solid and amorphous forms of (?)-halofenate.
    Type: Grant
    Filed: April 20, 2006
    Date of Patent: June 19, 2012
    Assignees: Metabolex, Inc., DiaTex, Inc.
    Inventors: Edward D. Daugs, Eric J. Hagen, Jason A. Hanko, David H. Louks
  • USE OF (-)(3-TRIHALOMETHYLPHENOXY)(4-HALOPHENYL) ACETIC ACID DERIVATIVES FOR TREATMENT OF INSULIN RESISTANCE, TYPE 2 DIABETES AND HYPERLIPIDEMIA
    Publication number: 20100093853
    Abstract: The present invention provides the use of (?)(3-trihalomethylphenoxy)(4-halophenyl)acetic acid derivatives and compositions in the treatment of insulin resistance, Type 2 diabetes and hyperlipidemia.
    Type: Application
    Filed: July 16, 2009
    Publication date: April 15, 2010
    Applicants: Metabolex, Inc., DiaTex, Inc.
    Inventors: KENNETH L. LUSKEY, JIAN LUO
  • USE OF (-) (3-TRIHALOMETHYLPHENOXY) (4-HALOPHENYL) ACETIC ACID DERIVATIVES FOR TREATMENT OF INSULIN RESISTANCE, TYPE 2 DIABETES, HYPERLIPIDEMIA AND HYPERURICEMIA
    Publication number: 20100093855
    Abstract: The present invention provides the use of (?)(3-trihalomethylphenoxy)(4-halophenyl)acetic acid derivatives and compositions in the treatment of insulin resistance, Type 2 diabetes, hyperlipidemia and hyperuricemia.
    Type: Application
    Filed: July 16, 2009
    Publication date: April 15, 2010
    Applicants: Metabolex, Inc., DiaTex, Inc.
    Inventors: Kenneth L. Luskey, Jian Luo
  • Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
    Patent number: 7576131
    Abstract: The present invention provides the use of (?) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives and compositions in the treatment of insulin resistance, Type 2 diabetes, hyperlipidemia and hyperuricemia.
    Type: Grant
    Filed: March 4, 2003
    Date of Patent: August 18, 2009
    Assignees: Metabolex, Inc., DiaTex, Inc.
    Inventors: Kenneth L. Luskey, Jian Luo
  • USE OF (-)(3-TRIHALOMETHYLPHENOXY)(4-HALOPHENYL) ACETIC ACID DERIVATIVES FOR TREATMENT OF INSULIN RESISTANCE, TYPE 2 DIABETES AND HYPERLIPIDEMIA
    Publication number: 20070270490
    Abstract: The present invention provides the use of (?)(3-trihalomethylphenoxy)(4-halophenyl)acetic acid derivatives and compositions in the treatment of insulin resistance, Type 2 diabetes and hyperlipidemia.
    Type: Application
    Filed: March 22, 2007
    Publication date: November 22, 2007
    Applicants: Metabolex, Inc., DiaTex, Inc.
    Inventors: Kenneth Luskey, Jian Luo
  • Use of (-)(3-trihalomethylphenoxy)(4-halophenyl) acetic acid derivatives for treatment of insulin resistance, Type 2 diabetes and hyperlipidemia
    Publication number: 20050075396
    Abstract: The present invention provides the use of (?) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives and compositions in the treatment of insulin resistance, Type 2 diabetes and hyperlipidemia.
    Type: Application
    Filed: September 10, 2003
    Publication date: April 7, 2005
    Applicants: Metabolex, Inc., DiaTex, Inc.
    Inventors: Kenneth Luskey, Jian Luo
  • Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, Type 2 diabetes, hyperlipidemia and hyperuricemia
    Publication number: 20030220399
    Abstract: The present invention provides the use of (−) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives and compositions in the treatment of insulin resistance, Type 2 diabetes, hyperlipidemia and hyperuricemia.
    Type: Application
    Filed: March 4, 2003
    Publication date: November 27, 2003
    Applicants: Metabolex, Inc., DiaTex, Inc.
    Inventors: Kenneth L. Luskey, Jian Luo
  • Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
    Patent number: 6646004
    Abstract: The present invention provides the use of (−)(3-trihalomethylphenoxy)(4-halophenyl)acetic acid derivatives and compositions in the treatment of insulin resistance, Type 2 diabetes and hyperlipidemia.
    Type: Grant
    Filed: October 31, 2000
    Date of Patent: November 11, 2003
    Assignees: Metabolex, Inc., DiaTex, Inc.
    Inventors: Kenneth L. Luskey, Jian Luo
  • Use of (?) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
    Patent number: 6624194
    Abstract: The present invention provides the use of (−) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives and compositions in the treatment of insulin resistance, Type 2 diabetes, hyperlipidemia and hyperuricemia. It further provides (−) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives that are useful for the treatment of insulin resistance, Type 2 diabetes, hyperlipidemia and hyperuricemia.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: September 23, 2003
    Assignees: Metabolex, Inc., DiaTex, Inc.
    Inventors: Kenneth L. Luskey, Jian Luo, Zuchun Zhao